Cityslickers apperciate your clincial viewpoint and insights ... and based on my experience on the "business" side of the medical industry, I agree!

My hunch is that they probably have some "offers" ... just not "acceptable" offers, yet.

Probably a sliding scale of valuation and leverage?

The further RVX can get down the path toward regulatory acceptance and marketablity, the value rises ... so it helps to have operational funding to wait out some of those potential offers? ... and yes, let competition drive up the price as clarity on the future emerges? ... a game of chicken for BP's competing, and RVX/Investors ... with time on RVX's side "if" they can sustain operations through regulatory processes and some more miestones.

Per Fenix' post below, ... rooting REAL hard for regulatory to see the light, with break-through status given safety profile, even if a concurrent P4 is part of it ..... why not?! Given safety profile, and some of the data? ... I mean, wouldn't the drug be continually studies anyhow? Why not approve it and call it a market concurrent P4? ... that's my vote! ... maybe I'm a bit biased tho? :)